Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
Sponsor: Intra-Cellular Therapies, Inc.
Summary
Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.
Official title: An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to Less Than 13 Years, Diagnosed With Autism Spectrum Disorder
Key Details
Gender
All
Age Range
5 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
33
Start Date
2024-05-10
Completion Date
2025-11-26
Last Updated
2026-07-24
Healthy Volunteers
No
Conditions
Interventions
Lumateperone 10.5 mg capsule
Lumateperone 10.5 mg capsule, oral administration
Lumateperone 21 mg capsule
Lumateperone 21 mg capsule, oral administration
Lumateperone 5 mg ODT
Lumateperone 5 mg ODT, oral administration
Lumateperone 10.5 mg ODT
Lumateperone 10.5 mg ODT, oral administration
Lumateperone 15.5 mg ODT
Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
Lumateperone 21 mg ODT
Lumateperone 21 mg ODT, oral administration
Locations (7)
APG Research LLC
Orlando, Florida, United States
CenExeli Research LLC
Atlanta, Georgia, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
CenExeli Research LLC 1
Savannah, Georgia, United States
Midwest Research Group
Saint Charles, Missouri, United States
Alivation Research LLC
Lincoln, Nebraska, United States
Core Clinical Research
Everett, Washington, United States